ArticleBMC microbiology2025
Mechanistic insights into Rottlerin's inhibition of MrkH-mediated biofilm and capsule formation in Klebsiella pneumoniae.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKlebsiella pneumoniae is a notoriously aggressive opportunistic pathogen within the Enterobacteriaceae family, with virulence factors, including polysaccharide capsules, lipopolysaccharide (LP>S), siderophores, and biofilm formation, serving as essential determinants of the pathogenicity. Biofilms in particular are associated with substantial nosocomial and community-acquired illnesses; moreover, the capsule enveloping K. pneumoniae's surface further contributes to its viscous phenotype and virulence. This study explores the possible anti-virulence properties of the plant-derived compound Rottlerin using molecular docking aimed at a crucial protein implicated in biofilm formation in Klebsiella pneumoniae. Here, we investigate the molecular foundation of ligand-specific modulation of MrkH, a c-di-GMP-responsive transcriptional activator essential for biofilm development in Klebsiella pneumoniae. Utilizing a comprehensive methodology that encompasses molecular docking, dynamic modeling, and structural analysis, we evaluated the native c-di-GMP dimer-MrkH complex against the binding orientation and conformational impacts of the plant-derived chemical Rottlerin.
resultsThe sub-MIC of Rottlerin shows an inhibitory effect against some virulence factors, leading to a 57.6% decrease in biofilm formation, and a reduction in capsule size by 85.6% was observed; moreover, Rottlerin also significantly downregulated genes associated with these virulence factors. Through extensive molecular modeling (e.g., inverse docking, molecular dynamics simulation, and structural analysis), the c-di-GMP dimer was found to bind to rottlerin with a remarkable specificity, establishing stabilizing hydrogen bonds and distinctive π-cation interactions with Arg107 and Arg111, securing MrkH in an activation-ready configuration. Conversely, Rottlerin binds to the same pocket mainly via dual π-cation interactions with Arg107 and supplementary localized contacts; however, it is deficient in the extensive interaction network necessary for complete allosteric activation. Dynamic profiling by RMSF and PCA indicate that Rottlerin-bound MrkH exhibits an intermediate level of flexibility between the totally stable c-di-GMP-bound state and the highly dynamic apo form.
conclusionThese results substantiate the function of Rottlerin as a non-activating competitive binder, providing mechanistic insight into its potential as an anti-biofilm agent and building a foundation for the rational design of small-molecule inhibitors aimed at c-di-GMP regulatory pathways. Our findings demonstrate that Rottlerin is a potent and efficient sub-MIC inhibitor of K. pneumoniae's ability to form biofilms and capsules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.